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Objective: To investigate the effect of glycosylated he-
moglobin, age, sex, hypertension, bodymass index,waist-
hip ratio, serum lipid levels, and smoking on the inci-
dence of retinopathy in personswithnormal and abnormal
glucose metabolism.
Methods: The incidence of retinopathy was determined
in 233 individuals, aged 50 to 74 years, by ophthalmos-
copy and fundus photography at baseline and after an av-
erage follow-up of 9.4 years. Relative risks for retinopa-
thy, estimated by odds ratios, were calculated for tertiles
of cardiovascular risk factors at baseline. Logistic regres-
sion analysis was used, without and with adjustment for
age, sex, hypertension, and glucose metabolism.
Results:The cumulative incidences of retinopathy among
individuals with normal, impaired, and diabetic glucose
metabolism were 7.3%, 13.6%, and 17.5%, respectively.
Adjusted odds ratios for retinopathywere 2.36 (95% con-
fidence interval, 1.02-5.49) for hypertension and 3.29
(95% confidence interval, 1.11-9.72) and 8.67 (95% con-
fidence interval, 1.85-40.60) for the highest tertiles of gly-
cosylated hemoglobin level and waist-hip ratio, respec-
tively.No consistent or statistically significant associations
with retinopathy were present for age, sex, body mass
index, smoking, and serum levels of triglycerides and total,
high-density lipoprotein, and non–high-density lipopro-
tein cholesterol (P.05 for all).
Conclusion: Glycemia, hypertension, and abdominal
obesity are determinants for retinopathy in a general
population.
Arch Ophthalmol. 2003;121:245-251
T HE DIAGNOSTIC value of theplasma glucose level fordiabetes mellitus (DM) ischosen based on a sharp in-crease of the prevalence of
retinopathy above that level.1 It is not an
absolute threshold, because retinopathy
occurs, albeit at a lower prevalence, also
at lower glucose levels.1 Intervention stud-
ies in diabetic patients have shown that
tight glucose control reduces the risk of
retinopathy, although patients newly di-
agnosed as having type 2DM in theUnited
KingdomProspectiveDiabetes Study,2with
a mean glycosylated hemoglobin (HbA1c)
level of 7.0%, still had an absolute risk of
7.9 per 1000 patient-years for retinal pho-
tocoagulation. In addition, the United
Kingdom Prospective Diabetes Study3
showed that tight blood pressure control
effectively reduced the risk of retinopa-
thy. Reports3-15 on the incidence of (dia-
betic) retinopathy and risk factor analy-
ses aremainly based on findings in diabetic
patients. These studies reported HbA1c
level, duration of DM, use of insulin, and
blood pressure as determinants of reti-
nopathy. Moreover, hypertension seems
to be a risk factor, particularly at lower fast-
ing plasma glucose levels.9 However, only
a few studies16,17 have investigated risk fac-
tors other than hyperglycemia for the in-
cidence of retinopathy in a general popu-
lation sample, including people with a
normal glucose metabolism (NGM) or an
impaired glucose metabolism (IGM).
Therefore, we studied the 10-year cu-
mulative incidence of retinopathy in in-
dividuals with baseline NGM or IGM and
in patients with type 2 DM. This study
evaluates the effect of glycemic status, hy-
pertension, dyslipidemia, obesity, and
smoking at baseline for incident retinopa-
thy during 10 years of follow-up.
METHODS
SUBJECTS
Subjects were selected from theHoorn study,18
a population-based cohort study on glucoseme-
tabolism that has been reported in detail pre-
viously. In brief, a random selection of 3553
inhabitants aged 50 to 74 years from Hoorn,
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the Netherlands, was invited, and 2484 white individuals par-
ticipated. The fasting plasma glucose level was measured, and
all individuals not treated with oral hypoglycemic agents or in-
sulin underwent a 75-g oral glucose tolerance test (OGTT) to
measure the 2-hour postload plasma glucose level. A sample
of 708 individuals, stratified for age, sex, and postload plasma
glucose levels after the OGTT, was randomly selected to study
diabetic complications and possible determinants. Subjects with
a postload plasma glucose level of 135 mg/dL or higher (7.5
mmol/L) were oversampled to increase the power of the study.
Individuals in this sample who did not receive pharmacologi-
cal treatment for DM underwent a second OGTT within 3 to 5
weeks after the first OGTT. A baseline ophthalmological ex-
amination was performed in 626 people from November 24,
1989, to March 9, 1992, and 478 individuals also underwent
fundus photography. Retinopathy was detected in 85 individu-
als, and essential information was missing for 1 person.
Four hundred sixty-three individuals who were still alive
and did not move out of the region received a personal written
invitation with additional information for a second examina-
tion session for DM andDM-related complications in 2000 and
2001. The session consisted of 4 visits to the Diabetes Re-
search Center in Hoorn, with an ophthalmological examina-
tion, including ophthalmoscopy combined with fundus pho-
tography, at the second visit. People who did not respond to
the written invitation were contacted by telephone. This ar-
ticle describes the 540 individuals who did not have retinopa-
thy at baseline. Of these individuals, 233 participated in the sec-
ond ophthalmological examination (56.3%of surviving subjects,
still living in the region).Of the 307 nonparticipants, 91 (29.6%)
had died and 35 (11.4%) had moved out of the region. Among
the 181 remaining nonparticipants, the most frequently stated
reasons for nonparticipationwere lack ofmotivation and health
ormobility problems. The nonparticipants (including thosewho
died) had a higher baseline age (65.7 vs 62.1 years), fasting glu-
cose level (120 vs 112 mg/dL [6.7 vs 6.2 mmol/L]), and HbA1c
level (5.90% vs 5.67%), and more of them experienced hyper-
tension (42.3% vs 30.5%), compared with participants at fol-
low-up (P.05 for all differences). The Hoorn study was ap-
proved by the Ethical Review Committee of the VU University
Medical Center. Written informed consent was obtained from
all participants.
OPHTHALMOLOGICAL EXAMINATIONS
After mydriasis with tropicamide and phenylephrine hydro-
chloride eyedrops, the retina was examined by ophthalmos-
copy (indirect ophthalmoscopy and biomicroscopy). In addi-
tion, 2 photographs were made of each eye, one centered on
the macula and the other nasal on the optic disc.
Examinations at baselinewere performed by ophthalmolo-
gists of theDepartment ofOphthalmology, VUUniversityMedi-
cal Center. Baseline photographywas performedwith a 45° fun-
dus camerawith a green filter (KowaPro;KowaOptical Industry,
Tokyo, Japan), and retinopathy was graded from 1111-cm
photographs from black-and-white 35-mm films (Kodak
Tri-X400 ASA; Eastman Kodak, Rochester, NY).
At follow-up, a fundus examination and photography of
the same fields as at baseline were performed by an ophthal-
mologically trained physician (H.A.v.L.). A 45° nonmydriatic
retinal camera (CR5; Canon Inc, Tokyo) was used, interfaced
to a 3CCD color video camera (DXC-950P; Sony Corp, Tokyo).
The quality of each photograph was checked immediately on
a connected color video monitor (Trinitron; Sony Corp), and
a new photographwas taken if the quality was insufficient. The
photographswere digitized, compressed (10:1 JPEG [Joint Pho-
tographicExpertsGroup]), and stored on adisc using amagneto-
optical videodisk recorder (MV-300P Viewfile system; TEAC
Corp, Tokyo). These follow-up photographs were graded for
retinopathy using a 43-cmmonitor (resolution, 600800 pix-
els; 16-bit color) and a software program (Adobe Photoshop
4.0 LE).
Baseline and follow-up photographs were analyzed inde-
pendently by an ophthalmologically trained physician (H.A.v.L.)
and an ophthalmologist (A.C.M. or B.C.P.P.). The agreement
for the presence of retinopathy from digital images at fol-
low-up was 96.0% (, 0.59) for right eyes and 97.3% (, 0.71)
for left eyes. In cases of disagreement, the independent judg-
ment of another ophthalmologist (A.C.M. or B.C.P.P.) was de-
cisive. All graders were masked for patient characteristics such
as age, type of glucose metabolism, and presence of hyperten-
sion. Retinopathy was considered present when at least onemi-
croaneurysm, hemorrhage, or hard exudate was present (mini-
mal nonproliferative retinopathy) or occurred in combination
with cotton-wool exudates, venous beading, or intraretinal mi-
crovascular abnormalities (moderate nonproliferative retinopa-
thy) or, in case of neovascularization, fibrous proliferation or
laser coagulation scars detected by photography or ophthal-
moscopy, according to the classification that was used in the
EURODIAB (EUROpe and DIABetes) study.19 Six individuals
with symptoms of hypertensive retinopathy and 7 with symp-
toms of vascular occlusion (flame-shaped hemorrhages) were
scored as not having (diabetic) retinopathy. In each subject,
the retinopathy level of the worst eye, according to ophthal-
moscopy or fundus photography, was scored. In case of dis-
crepancies between ophthalmoscopy and photography, oph-
thalmoscopic findings were corrected if corresponding
photographically visible retinal lesions seemed to be symp-
toms of other underlying pathological conditions.
OTHER BASELINE ASSESSMENTS
Fasting and 2-hour postload venous plasma glucose levels were
determined with a glucose dehydrogenase method (Merck,
Darmstadt, Germany). For statistical analyses, the mean of 2
fasting and 2 two-hour glucose levels was used. Subjects were
classified into 3 categories (NGM, IGM, or DM), in accor-
dance with the World Health Organization 1999 criteria.20
Known diabetic individuals at baseline (n=16), treated with
oral glucose-lowering medication, insulin, or a diet, were in-
cluded in the DM group. Glycosylated hemoglobin and lipid
levels were determined in the fasting blood sample during the
first OGTT. The HbA1c level was determined by ion-exchange
high-performance liquid chromatography (Modular Diabetes
Monitoring system; Bio-Rad, Veenendaal, theNetherlands) (nor-
mal range, 4.3%-6.1%). Total cholesterol, high-density lipo-
protein (HDL) cholesterol (after precipitation of the low- and
very low-density proteins), and triglycerides weremeasured by
enzymatic techniques (Boehringer-Mannheim, Mannheim,
Germany). The non-HDL cholesterol level was calculated by
subtracting the HDL cholesterol level from the total choles-
terol level. The non-HDL cholesterol level, which includes the
low-density lipoprotein cholesterol level and the very low-
density lipoprotein remnants, was chosen because it may be a
more reliable predictor for mortality from cardiovascular dis-
ease than low-density lipoprotein cholesterol level alone.21 Sys-
tolic and diastolic (Korotkoff V) blood pressure measure-
ments were determined on the right arm of seated subjects, after
at least 5 minutes of rest, using a random-zero sphygmoma-
nometer. The average of 4 measurements was used for analy-
sis. Hypertension was defined as a systolic pressure of 160
mm Hg or higher, a diastolic pressure of 95 mm Hg or higher,
and/or the use of antihypertensive medication. Height, weight,
body mass index (BMI), and waist-hip ratio (WHR) were
determined to assess the presence of obesity and fat distribu-
tion. Information on smoking behavior and use of medication
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was obtained from a questionnaire completed by the partici-
pants.
STATISTICAL ANALYSES
The cumulative incidence of retinopathy was calculated in cat-
egories of glucose metabolism. The baseline characteristics of
individuals with retinopathy at follow-up were compared with
those of individuals who had not developed retinopathy, by us-
ing a t test, a 2 test with continuity correction, or a Mann-
Whitney test in case of a skeweddistribution (triglyceride levels).
P.05 (2 sided) was considered statistically significant. Logis-
tic regression was used to calculate the odds ratios (ORs) for
retinopathy, with a 95% confidence interval, for women com-
pared with men, for 10-year age groups compared with the
youngest age group (50-59 years), for IGM and DM compared
with NGM, for tertiles of HbA1c level compared with the low-
est tertile, and for individuals with hypertension comparedwith
those without hypertension. The OR is a good estimate for the
relative risk when the cumulative incidence is less than ap-
proximately 20%.22 When the cumulative incidence is higher,
the OR is an overestimation of the relative risk. The univariate
association of lipid levels, obesity, and smoking with retinopa-
thy was investigated by calculating ORs for tertiles of triglyc-
erides; total, HDL, and non-HDL cholesterol levels; BMI; and
WHR compared with the lowest tertile, and for smokers and
ex-smokers compared with never smokers. Tertiles of deter-
minants were analyzed to evaluate possible linear trends. Odds
ratios were adjusted for age and sex and subsequently for hy-
pertension and glucose metabolism (glucose metabolism cat-
egory or HbA1c level). Hypertension was chosen for adjust-
ment, because it combined systolic and diastolic blood pressure
measurements and the use of antihypertensive medication in
one variable. To investigate the effect of DM duration, the OR
for incident retinopathy was calculated per year with DM in
individuals with known DM. In all analyses, Statistical Prod-
uct and Service Solutions software, version 10.1 for Windows
(SPSS Inc, Chicago, Ill), was used.
RESULTS
Twenty-seven (11.6%) of 233 individuals had devel-
oped retinopathy after an average follow-up of 9.4 years
(range, 7.9-11.0 years). Twenty-four people had mini-
mal nonproliferative retinopathy, and one individual had
moderate nonproliferative retinopathy; 2 people were
treated with photocoagulation. For baseline character-
istics, individualswhodeveloped retinopathy had a higher
mean age, HbA1c level, systolic blood pressure,WHR, and
waist circumference, and they more frequently had hy-
pertension, than individuals who did not develop reti-
nopathy (Table 1). If we consider only nondiabetic in-
dividuals, serum fasting glucose level (P=.04), diastolic
blood pressure (P=.009), and BMI (P=.04) were signifi-
cantly higher in individuals with retinopathy as well, but
the mean age was not (data not shown).
The cumulative incidence of retinopathy was simi-
lar for men and women, and was highest in those aged
Table 1. Baseline Characteristics of People With and Without Incident Retinopathy After 10 Years*
Baseline Characteristic
Retinopathy
P Value
Yes
(n = 27)
No
(n = 206)
NGM/IGM/DM ratio 8:9:10 102:57:47 . . .
Female sex† 48.1 46.6 .99
Age, y 64.8 (± 6.1) 61.8 (± 6.8) .03
Glucose level, mg/dL
Fasting 123 (± 32) 110 (± 31) .08
2 h‡ 153 (± 59) 146 (± 72) .64
HbA1c level, % 6.1 (± 1.0) 5.6 (± 1.0) .03
Blood pressure, mm Hg
Systolic 141.6 (± 17.7) 133.7 (± 16.4) .02
Diastolic 84.6 (± 9.9) 81.5 (± 9.4) .11
Hypertension† 51.9 27.7 .02
Use of antihypertensive agents† 37.0 18.9 .06
BMI 27.8 (± 3.9) 26.6 (± 3.4) .10
WHR 0.96 (± 0.07) 0.91 (± 0.09) .01
Circumference, cm
Waist 97.8 (± 10.1) 92.1 (± 10.8) .01
Hip 102.0 (± 8.1) 101.3 (± 6.2) .60
Cholesterol level, mg/dL
Total 259 (± 49) 254 (± 40) .54
HDL 47 (± 10) 50 (± 14) .27
Non-HDL 212 (± 49) 203 (± 41) .30
Triglycerides, mg/dL§ 133 (± 89) 142 (± 89) .69
(Ever) smoked cigarettes† 70.4 58.7 .34
Abbreviations: BMI, body mass index (calculated as weight in kilograms divided by the square of height in meters); DM, diabetes mellitus; HbA1c, glycosylated
hemoglobin; HDL, high-density lipoprotein; IGM, impaired glucose metabolism; NGM, normal glucose metabolism; WHR, waist-hip ratio.
SI conversion factors: To convert cholesterol (total, HDL, and non HDL) to millimoles per liter, multiply by 0.0259; to convert glucose (fasting and 2-hour)
to millimoles per liter, multiply by 0.0555; and to convert triglycerides to millimoles per liter, multiply by 0.0113.
*Data are given as mean (± SD) unless otherwise indicated.
†Data are given as percentage of individuals.
‡Individuals with known DM were excluded.
§Data are given as median (± interquartile range).
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60 to 69 years (Table 2). In individuals with IGM, the
cumulative incidence was almost twice as high as in in-
dividuals with NGM (P= .17). The cumulative inci-
dence increased from6.0% for those in the lowest to 20.7%
for those in the highest tertile of HbA1c level (P=.005 for
trend), and was significantly higher in people with hy-
pertension than in people without hypertension (Table
2). A univariate logistic regression analysis showed higher
ORs for the development of retinopathy in older per-
sons (Table 2). The crude ORs for retinopathy were 2.01
and 2.71 for individuals with IGM and DM, respec-
tively, compared with individuals with NGM. Risk also
increased with HbA1c level, particularly for those in the
highest tertile of HbA1c level, and more than doubled in
individuals with hypertension compared with individu-
als without hypertension (Table 2). After adjustment for
age and sex, and for age, sex, glucose metabolism cat-
egory, and hypertension, inmultivariatemodels, theORs
did not change considerably.Whenwe limited the analy-
ses to the nondiabetic subjects, the OR for those in the
highest tertile of HbA1c level compared with those in the
lowest tertile was 3.95, and the OR for those with hy-
pertension compared with those without hypertension
was 3.84 (Table 3).
No associations were observed between BMI, se-
rum triglycerides, and total, HDL, and non-HDL choles-
terol levels and incident retinopathy (Table4). The ORs
for retinopathy were significantly higher for those in the
higher tertiles of WHR, which did not change after ad-
justment for age, sex,HbA1c level, andhypertension (Table
4). Cigarette smokers and ex-smokers had higher, but
nonsignificant, ORs for incident retinopathy than never
smokers, particularly after adjustment for age, sex, HbA1c
level, and hypertension. When we limited the analyses
to the nondiabetic subjects, comparable results were ob-
served (data not shown).
Regarding DM duration, the OR for incident reti-
nopathy was 1.06 (95% confidence interval, 0.73-1.52)
per year of DM among persons with known DM. The
number of persons with known DM was, however, too
small (n=16) for a detailed analysis of this risk factor.
COMMENT
Not only patients with type 2 DM, but elderly individu-
als with IGM andNGM in general, have a substantial risk
of developing retinopathy. Our findings indicate that a
high HbA1c level, hypertension, and a highWHR are de-
terminants of the incidence of retinopathy.
Little research has been performed on the incidence
of (diabetic) retinopathy and its association with cardio-
vascular risk factors in populations, including nondia-
betic people as well. To our knowledge, only 2 studies de-
scribe the incidence of retinopathy in nondiabetic subjects.
The Beaver Dam Eye Study17 reports a 5-year incidence of
6.0%, and a study16 in Finland reports an incidence of 6.5%
after 10 years, which agrees with the observations for in-
dividuals with NGM in the present study. In the present
study, the incidence of retinopathywas comparable inmen
and women, in accordance with findings in diabetic pa-
tients.9,11,13 In contrast to these studies, however, the inci-
dence in our study had a tendency to increase with older
age in the 50- to 70-year-old people. Our study confirmed
the well-known positive association between HbA1c level
Table 2. Incidence of and ORs for Incident Retinopathy by Categories of Cardiovascular Risk Factors
Risk Factor at Baseline Incidence, %*
OR†
Crude
Adjusted
1 2
Sex
Male‡ 11.3 (124) 1.00 1.00 1.00
Female 11.9 (109) 1.06 (0.48-2.38) 0.97 (0.43-2.19) 0.99 (0.43-2.28)
Age, y
50-59‡ 7.0 (100) 1.00 1.00 1.00
60-69 16.3 (98) 2.59 (1.02-6.61) 2.60 (1.02-6.67) 2.23 (0.85-5.85)
70 11.4 (35) 1.71 (0.47-6.25) 1.72 (0.47-6.34) 1.46 (0.39-5.56)
Glucose metabolism category
NGM‡ 7.3 (110) 1.00 1.00 1.00
IGM 13.6 (66) 2.01 (0.74-5.50) 1.90 (0.69-5.25) 1.68 (0.60-4.71)
DM 17.5 (57) 2.71 (1.01-7.31) 2.36 (0.86-6.48) 1.91 (0.68-5.41)
HbA1c level, %
4.3-5.2‡ 6.0 (83) 1.00 1.00 1.00
5.3-5.7 7.4 (68) 1.24 (0.34-4.47) 1.18 (0.32-4.28) 1.13 (0.31-4.19)
5.8-13.1 20.7 (82) 4.08 (1.43-11.65) 3.80 (1.31-11.00) 3.29 (1.11-9.72)
Hypertension
No‡ 8.0 (162) 1.00 1.00 1.00
Yes 19.7 (71) 2.82 (1.25-6.36) 2.66 (1.17-6.06) 2.36 (1.02-5.49)
Abbreviations: DM, diabetes mellitus; HbA1c, glycosylated hemoglobin; IGM, impaired glucose metabolism; NGM, normal glucose metabolism; OR, odds ratio.
*Data in parentheses are the absolute number at risk.
†Data in parentheses are 95% confidence intervals. The crude OR is the OR after univariate logistic regression, and the adjusted OR is the OR after adjustment
for sex and age (1) and for sex, hypertension, age, and glucose metabolism category (2). The determinant HbA1c level was adjusted for sex, hypertension, and age
only.
‡Referent.
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and retinopathy.4,10,12,13,15 The 2-hour serum glucose value
was not associated with incident retinopathy. The esti-
mated risk for developing retinopathy after 10 years in in-
dividualswith hypertensionwasmore than 2 times as high
as in individuals without hypertension, which remained
after adjustment for age, sex, and glucose metabolism
category. This is in line with previous findings of incident
retinopathy in studies6,7,9,13 of diabetic patients and in the
2 studies16,17 that included nondiabetic individuals.
Type 2 DM is often associated with dyslipidemia, in-
cludingelevated serumtriglyceride levels and lowHDLcho-
lesterol levels. The present study did not find a statisti-
cally significant associationbetween serum triglyceride and
total, HDL, and non-HDL cholesterol levels and the devel-
opment of retinopathy. Associations between cholesterol
or triglyceride levels and the incidence of retinopathy, al-
though not always statistically significant in multivariate
risk models, were described in studies7,12,15,23 that in-
cludeddiabeticpatients.Cross-sectionaldata24,25 have shown
that hard exudates in particular are associated with el-
evated cholesterol levels. In the present study, the num-
berof individualswith incidenthard exudateswas too small
(n=6) for detailed analysis.
The WHR is an indicator for central obesity and is
associatedwith insulin resistance.26 A highWHR, but not
BMI, seemed to indicate a high risk of developing reti-
nopathy after 10 years, independent of age, sex, HbA1c
level, and hypertension. In particular, a large waist cir-
cumference seems to play a role, because the mean hip
circumference did not differ much between individuals
with and without retinopathy (Table 1). The WHR was
also an independent risk factor in the diabetic patients
in the EURODIAB study.12,15 In line with our study, no
consistent associations between BMI and incident reti-
nopathy have been observed in studies9,16 that included
diabetic patients. A positive association between BMI
and retinopathy was found in the Diabetes Control and
Complications Trial4 cohort of patients with type 1 DM,
but a negative association was found in diabetic Pima
Indians.7 The present findings of the combination of
WHR, HbA1c level, and hypertension as risk factors for
retinopathy may suggest that insulin resistance or asso-
ciated factors are implicated in the pathogenesis of
retinopathy.
The present study mainly considered early phases
of retinopathy. Retinal hemorrhages and exudates at this
stage could be the first symptoms of hypertensive reti-
nopathy, during which the vasoconstrictive phase is not
expressed.27 This could explain the strong association
with hypertension. However, independent associations
of hypertension were also found with proliferative
retinopathy in diabetic populations.7,15 Moreover, in the
present study, 8 of the 17 nondiabetic individuals who
developed retinopathy did not have hypertension. In ad-
dition, HbA1c level and WHR were risk factors in the
nondiabetic individuals.
Similar to other longitudinal cohort studieswith rela-
tively older populations, the associations between base-
line determinants and retinopathy may be underesti-
mated as a result of competing morbidity and mortality.
One of the limitations of this study is the relatively small
number of cases. Therefore, only the strongest associa-
tions with retinopathy are expected to be detected. Also,
there was a rather high nonparticipation rate of 43.7%
among the survivors in the region at follow-up. There
may be several possible explanations. First, in contrast
to previous population studies of the 60- to 85-year-old
population, two thirds of our original selected subco-
hort had IGMorDM at baseline.We observed that health
had considerably deteriorated in these groups, as also in-
dicated by the high mortality of 40.5% in patients with
known DM compared with 12.8% in those with NGM.
Furthermore, the present follow-up medical examina-
tion was rather extensive, and included several visits to
Table 3. Incidence of and ORs for Incident Retinopathy by Categories of Cardiovascular Risk Factors in People Without DM
Risk Factor at Baseline Incidence, %*
OR†
Crude
Adjusted
1 2
Sex
Male‡ 10.5 (95) 1.00 1.00 1.00
Female 8.6 (81) 0.80 (0.29-2.22) 0.72 (0.25-2.02) 0.75 (0.26-2.17)
Age, y
50-59‡ 6.0 (84) 1.00 1.00 1.00
60-69 14.7 (68) 2.72 (0.88-8.39) 2.85 (0.92-8.88) 2.58 (0.81-8.21)
70 8.3 (24) 1.44 (0.26-7.91) 1.54 (0.28-8.58) 1.36 (0.24-7.82)
HbA1c level, %
4.3-5.2‡ 6.3 (79) 1.00 1.00 1.00
5.3-5.7 6.8 (59) 1.08 (0.28-4.19) 1.08 (0.27-4.30) 1.02 (0.25-4.18)
5.8-13.1 21.1 (38) 3.95 (1.19-13.03) 4.50 (1.26-16.06) 3.54 (0.94-13.37)
Hypertension
No‡ 6.1 (131) 1.00 1.00 1.00
Yes 20.0 (45) 3.84 (1.38-10.68) 3.61 (1.28-10.17) 3.61 (1.28-10.17)
Abbreviations: DM, diabetes mellitus; HbA1c, glycosylated hemoglobin; OR, odds ratio.
*Data in parentheses are the absolute number at risk.
†Data in parentheses are 95% confidence intervals. The crude OR is the OR after univariate logistic regression, and the adjusted OR is the OR after adjustment
for sex and age (1) and for sex, age, and hypertension (2).
‡Referent.
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the research center. This may have been considered too
demanding, because the nonparticipants, in general, were
less healthy, had already visited hospitals or health care
centers more often, or had problems with mobility. The
selection due to morbidity and mortality may also be an
explanation for the relatively lower ORs for retinopathy
in the highest age group. In conclusion, this study shows
that a higher HbA1c level, hypertension, and abdominal
obesity, as indicated by a high WHR, are determinants
for the development of retinopathy. These results sug-
gest that, in addition to serum glucose control in dia-
betic patients, screening for hypertension and abdomi-
nal obesity and adequate treatment of these risk factors
might prevent retinopathy in diabetic and nondiabetic
individuals.
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